References
1. Lewiecki EM. New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Ther Adv Musculoskelet Dis.2018;10(11):209-223.
2. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.N Engl J Med. 2009;361(8):756-765.
3. Watts NB, Brown JP, Papapoulos S, et al. Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension. J Bone Miner Res.2017;32(7):1481-1485.
4. Zhu Y, Huang Z, Wang Y, et al. The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review. J Orthop Translat. 2020;22:7-13.
5. Sheedy KC, Camara MI, Camacho PM. Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis. Endocr Pract. 2015;21(3):275-279.
6. Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.Lancet Diabetes Endocrinol. 2018;6(6):445-454.
7. Gonzalez-Gay MA, Matteson EL, Castaneda S. Polymyalgia rheumatica.Lancet. 2017;390(10103):1700-1712.
8. Saag KG, Pannacciulli N, Geusens P, et al. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.Arthritis Rheumatol. 2019;71(7):1174-1184.
9. Tanaka Y, Takeuchi T, Soen S, et al. Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study. J Rheumatol. 2021;48(11):1663-1671.
10. Yanbeiy ZA, Hansen KE. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. Drug Des Devel Ther. 2019;13:2843-2852.
11. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther.1981;30(2):239-245.
12. Macchioni P, Catanoso MG, Pipitone N, Boiardi L, Salvarani C. Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. Rheumatology (Oxford).2009;48(12):1566-1569.
13. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies.Bone Res. 2018;6:15.
14. Malmstrom V, Catrina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting.Nat Rev Immunol. 2017;17(1):60-75.